Research
Hormonal
Obesity-induced adipose tissue fibrosis, driven by unresolved inflammation and hypoxia, restricts adipose expandability and contributes to insulin resistance and resistance to weight loss.
Focus on preventing fat tissue damage (fibrosis) rather than just losing weight. Strategies that reduce inflammation and improve vascularization in fat tissue may be more metabolically beneficial than weight loss alone, especially in severe obesity.
GoodSupportsHIGH confidence
With chronic obesity, adipose tissue undergoes major remodeling, which can ultimately result in unresolved chronic inflammation leading to fibrosis accumulation. These features drive local tissue damage and initiate and/or maintain multiorgan dysfunction.
Why this rating
The paper is a review citing numerous human and rodent studies, including genetic models and clinical observations.
Source
Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis
Geneviève Marcelin et al. · Journal of Clinical Investigation · 2019
DOI 10.1172/jci129192
narrative_reviewCited 269×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Promoting angiogenesis (healthy vascularization) in adipose tissue reduces inflammation and fibrosis, whereas suboptimal vascularization leads to hypoxia and insulin resistance.Good
- Bariatric surgery-induced weight loss does not resolve adipose tissue fibrosis and may even increase ECM deposition, potentially contributing to metabolic deterioration during weight rebound.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →